Form4insider filings, from the source

SEC Form 3 · accession 0001193805-17-001412

Protara Therapeutics, Inc. · TARA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
Director · Other
Deerfield Mgmt L.P.
Director · Other
DEERFIELD PARTNERS, L.P.
Director · Other
James E Flynn
Director · Other
Deerfield Mgmt III, L.P.
Director · Other
Deerfield Mgmt IV, L.P.
Director · Other
Period of report
Aug 2, 2017
Accepted (ET)
Aug 4, 2017 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001359931

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3holding———877,799IThrough Deerfield Private Design Fund III, L.P.
Common StockF1,F2,F3holding———149,676IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2,F3holding———110,557IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2,F3holding———86,867IThrough Deerfield Partners, L.P.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Convertible Preferred StockF1,F2,F3,F4—holding—————Common Stock16,082,018—I

Explanation of responses

Remarks

Jonathan Leff, a partner in Deerfield Management Company, serves as a director of the Issuer. Please see Joint Filer Information Statement attached as Exhibit 99 hereto. Exhibit List Exhibit 24 - Power of Attorney Exhibit 99 - Joint Filer Information Statement